- Home
- CHY vs MLYS Comparison
CHY vs MLYS Comparison
Compare CHY & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- MLYS
- Stock Information
- Founded
- CHY 2003
- MLYS 2019
- Country
- CHY United States
- MLYS United States
- Employees
- CHY N/A
- MLYS N/A
- Industry
- CHY Investment Managers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- CHY Finance
- MLYS Health Care
- Exchange
- CHY Nasdaq
- MLYS Nasdaq
- Market Cap
- CHY 839.8M
- MLYS 890.6M
- IPO Year
- CHY N/A
- MLYS 2023
- Fundamental
- Price
- CHY $11.24
- MLYS $40.05
- Analyst Decision
- CHY
- MLYS Strong Buy
- Analyst Count
- CHY 0
- MLYS 6
- Target Price
- CHY N/A
- MLYS $42.60
- AVG Volume (30 Days)
- CHY 128.3K
- MLYS 2.6M
- Earning Date
- CHY 01-01-0001
- MLYS 11-10-2025
- Dividend Yield
- CHY 10.11%
- MLYS N/A
- EPS Growth
- CHY N/A
- MLYS N/A
- EPS
- CHY N/A
- MLYS N/A
- Revenue
- CHY N/A
- MLYS N/A
- Revenue This Year
- CHY N/A
- MLYS N/A
- Revenue Next Year
- CHY N/A
- MLYS N/A
- P/E Ratio
- CHY N/A
- MLYS N/A
- Revenue Growth
- CHY N/A
- MLYS N/A
- 52 Week Low
- CHY $9.97
- MLYS $8.24
- 52 Week High
- CHY $12.16
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- CHY 66.14
- MLYS 85.36
- Support Level
- CHY $11.11
- MLYS $34.59
- Resistance Level
- CHY $11.25
- MLYS $39.20
- Average True Range (ATR)
- CHY 0.08
- MLYS 3.03
- MACD
- CHY 0.02
- MLYS 0.63
- Stochastic Oscillator
- CHY 98.89
- MLYS 99.33
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.